Harmony Biosciences (NASDAQ:HRMY) Cut to “Hold” at Truist Financial

Truist Financial lowered shares of Harmony Biosciences (NASDAQ:HRMY) from a buy rating to a hold rating in a report released on Monday, Marketbeat.com reports.

A number of other equities research analysts also recently weighed in on HRMY. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Mizuho set a $50.00 price target on Harmony Biosciences in a research note on Thursday, February 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft cut Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a report on Monday. Finally, UBS Group downgraded shares of Harmony Biosciences from a “buy” rating to a “neutral” rating and boosted their target price for the company from $43.00 to $46.00 in a research note on Wednesday, February 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Harmony Biosciences has an average rating of “Moderate Buy” and a consensus price target of $42.67.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $28.19 on Monday. Harmony Biosciences has a one year low of $25.52 and a one year high of $40.87. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.72. The stock has a fifty day moving average price of $36.36 and a 200 day moving average price of $34.15. The stock has a market cap of $1.62 billion, a P/E ratio of 10.40, a price-to-earnings-growth ratio of 0.26 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.46). The business had revenue of $243.78 million during the quarter, compared to the consensus estimate of $240.04 million. Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the firm earned $0.85 EPS. Analysts predict that Harmony Biosciences will post 2.43 earnings per share for the current year.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Sandip Kapadia sold 20,961 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $35.92, for a total value of $752,919.12. The SEC filing for this sale provides additional information. Insiders sold 50,640 shares of company stock worth $1,932,256 over the last 90 days. 23.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its stake in Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after acquiring an additional 643 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after purchasing an additional 602 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Harmony Biosciences in the fourth quarter worth $30,000. Parkside Financial Bank & Trust grew its position in Harmony Biosciences by 4,185.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock valued at $37,000 after purchasing an additional 1,130 shares in the last quarter. Finally, National Bank of Canada FI acquired a new stake in Harmony Biosciences in the 3rd quarter valued at $40,000. 86.23% of the stock is owned by institutional investors and hedge funds.

More Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and $55 price target (about +95% from the current level), a clear bullish endorsement that could attract buyers. HC Wainwright rating
• Positive Sentiment: Needham cut its target slightly (from $46 to $44) but kept a “buy” rating, leaving substantial upside (~+56%) — another vote of confidence from a sell-side shop. Needham rating
• Positive Sentiment: Company results show continuing commercial strength: Q4 revenue of $243.8M (+21% y/y) and full-year 2025 product revenue of $868.5M; management reiterated ~>$1B revenue guidance and expects WAKIX revenue around $1.0–$1.04B in 2026 — growth signals that support a longer-term bullish case. BusinessWire release
• Neutral Sentiment: Q4 EPS missed Street expectations ($0.38 vs. $0.84 est.), creating short-term earnings disappointment even as revenue beat; investors will be parsing whether the EPS miss reflects one-offs or structural margin pressure. Zacks earnings note
• Neutral Sentiment: Full earnings materials and call transcripts/slide deck are available for deeper analysis (useful for active investors deciding if the EPS miss changes the growth story). Earnings transcript
• Negative Sentiment: Bank of America cut its target to $28 and moved to “underperform” (roughly in line with the current level), a bearish signal that can pressure sentiment and reduce conviction among institutional holders. Bank of America note
• Negative Sentiment: Truist lowered its rating to “hold,” signaling more cautious institutional views after the quarter. Truist rating change
• Negative Sentiment: UBS trimmed its target to $36 and moved to “neutral” — another downward revision that reduces consensus upside and may weigh on momentum. UBS note
• Negative Sentiment: Analyst and market commentary is highlighting legal and generic risks around WAKIX; these longer-term downside scenarios are being re-priced by some investors. Yahoo coverage on legal/generic risks

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.